Article

Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomes

2024-01-07

Abstract excerpt

<h4>ABSTRACT</h4> Despite the clinical success of dozens of genetically targeted cancer therapies, the vast majority of patients with tumors caused by loss-of-function (LoF) mutations do not have access to these treatments. This is primarily due to the challenge of developing a drug that treats a disease caused by the absence of a protein target. The success of PARP inhibitors has solidified synthetic lethality (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4a9684b1-e3a4-5462-81d6-ad9bec373edb
DOI: 10.1101/2024.01.05.574245

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomesDOI 10.1101/2024.01.05.574245Read

Identifying chemogenetic interactions from CRISPR knockout screens with drugZSemantic proximity Read

Identifying chemogenetic interactions from CRISPR screens with drugZSemantic proximity Read

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeuticsSemantic proximity Read

CRISPR-enabled genetic screens identify synthetic lethal targets across frequently altered cancer driversSemantic proximity Read

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.Semantic proximity Read

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalitySemantic proximity Read

Methods and resources to access mutation-dependent effects on cancer drug treatment.Semantic proximity Read

A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization.Semantic proximity Read

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read

An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer DrugsSemantic proximity Read

CRISPR Functional Genomics in Precision Oncology: Integrating Single-Cell Multi-Omics for Cancer Vulnerability DiscoverySemantic proximity Read

Challenges and opportunities for drug repurposing in cancers based on synthetic lethality induced by tumor suppressor gene mutationsSemantic proximity Read